ABSTRACT
Introduction ere have been major improvements in the outcome for patients with Hodgkin’s lymphomas (HL) and non-Hodgkin’s lymphomas (NHLs) in recent years. Many factors have contributed to this improvement in outcome including advances in diagnostic and staging techniques as well as improved supportive care. e major contributor to improved outcome has been the development of systemic treatments with high anti-tumor activity and reduced short-and long-term toxicity. Systemic therapy using combination chemotherapy (with the addition of monoclonal antibodies in certain lymphoma subtypes) is now the primary treatment modality for most patients with HL and NHL, irrespective of the anatomic extent of their disease. e role of radiation therapy has diminished, although it remains an important component of therapy for certain patients with limited-stage disease.
